PATH is a global nonprofit dedicated to achieving health equity. With more than 40 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales up innovative solutions to the world’s most pressing health challenges.

PATH’s Medical Device and Health Technology (MDHT) program is currently looking for a Market Shaping Officer in Kenya to carry out activities under the new Accelerating Measurable Progress and Leveraging investments for PPH Impact (AMPLI-PPHI) project which is expected to start in April 2022. The Market Shaping Officer in Kenya is expected to work closely with the Senior Commercialization Officer in MDHT who is leading the project activities at PATH.

The Market Shaping Officer will be responsible for coordinating/managing country-level activities to make sure the required outputs are delivered with high quality and on time.

Key Duties and Responsibilities:

• Closely working with the project lead, conduct due diligence analyses of short-listed manufacturers, which will be identified during the GAD process, select manufacturers, and engage with them to ensure that they will supply misoprostol and TXA in the four target and 16 influence countries, in accordance with Unitaid’s Global Access Principles.
• Continue to monitor or help monitor selected manufacturers for misoprostol and TXA as well as Ferring Pharmaceuticals so they will continue to ensure equitable availability, affordable pricing, relevant packaging and standard labeling of the drugs.
• Support collection of market intelligence, data analysis, development of assumptions for market sizing, and development of business cases to incentivize HSC, TXA and misoprostol manufacturers to commit to UNITAID’s Global Access Principles.
• Gather relevant financing strategies and options currently available in the four target countries and help identify those to which the three PPH drugs should be incorporated.
• Help engage the Global Financing Facility and other development partners to identify feasibility of potential catalytic financial resources for drug procurement.
• Understand the PV systems, how SAE/Serious Adverse Reaction (SAR) are reported, what types of data are currently reported, what manufacturers’ labeling information are for the three PPH drugs. Work with Jhpiego and FIGO to incorporate identification of SAE/SAR related to the three PPH drugs and proper reporting of those to relevant regulatory authorities into the training programs/materials for healthcare workers. Also, where PV systems exist, develop a report with recommendations on how to leverage the PV systems for the three PPH drugs.
• Support subcontractors who will work on PATH’s SOW Activity 5 (Develop VBP guidance for the three PPH drugs and provide interactive workshops to procurement agencies’ staff in the target countries) and Activity 6 (Optimize in-country supply chains at all levels of the health system) to ensure that their activities are completed on time and with high quality results. This might include regularly communicating with them to understand their progress, helping them engage relevant stakeholders, collect data that could augment their work, and support logistics related to workshops.
• Regularly communicate with the project lead to update on the progress of the project. Foresee potential risks/challenges, inform the project lead of them proactively, and identify/propose solutions to mitigate them.
• Participate in project meetings and help write reports to the prime or funder as needed.